Slide 1: Simplifying Progress: This is Sartorius
Simplifying Progress This is Sartorius 2026
Slide 2: Our purpose: Better health for more people
Our purpose: Better health for more people We empower scientists and engineers to simplify and Mission accelerate progress in life science and bioprocessing, enabling the development of new and better therapies and more affordable medicine. 2
Slide 3: Sartorius in 2025 numbers
Sartorius in 2025 numbers ~€3.5bn Sales revenue 29.7% Profit margin1 14,000+ Employees ~€440mn 60+ 150+ Investments Locations worldwide Years of experience 1 Underlying EBITDA margin 3
Slide 4: More than 14,000 employees united by strong values
More than 14,000 employees united by strong values 108 Nationalities Sustainability Openness Enjoyment Growing profitably and Driving change Working in an energetic acting responsibly towards and progress and rewarding Younger than all stakeholders internally and externally environment 51% 40 years
Slide 5: Two product offerings with a clear focus on the life science industry
Two product offerings with a clear focus on the life science industry Offers a wide array of innovative technologies for the manufacture of biopharmaceuticals and vaccines as well as cell ~80% Sales 2025 ~20% and gene therapeutics Bioprocess Solutions ~€3.5bn Lab Products & Services Specializes in e
Slide 6: Simplifying Progress: Enabling the discovery and production of biopharmaceuticals
Simplifying Progress: Enabling the discovery and production of biopharmaceuticals Bioprocess Solutions Molecule Cell line and Upstream & development process development downstream production Quality | Testing | Validation Lab Products & Services 6
Slide 7: What are biopharmaceuticals?
What are biopharmaceuticals? Chemical drugs Advantages of Aspirin biopharmaceuticals (C9H8O4) Target only diseased cells Administered Fewer side effects Small, simple Obtained via molecules chemical synthesis in various ways Allow first-time or improved treatment of Biopharmaceuticals illnesse
Slide 8: The promises of biologics: From established to new concepts
The promises of biologics: From established to new concepts Breakthroughs at an ever-increasing pace and new forms of treatment offer hope for patients 1796 1818 1982 1986 2012 / 2017 2020 2023 Blood Recombinant Monoclonal Cell & gene mRNA CRISPR Vaccines products proteins antibodies therapies vacci
Slide 9: Many biotech medications are highly effective, but very expensive
Many biotech medications are highly effective, but very expensive Rheumatism Blood cancer Leukodystrophy Monoclonal antibodies CAR-T cell therapy Gene therapy ~€12,000 ~€240,000 ~$4.25mn Annual cost of treatment in GER Cost per treatment in Europe Cost per treatment in the USA 9
Slide 10: Only one out of 10,000 new drug candidates reaches the market
Only one out of 10,000 new drug candidates reaches the market Drug discovery Process development Market approval Commercial production >€2bn ~10% >10 years Average costs of developing Probability of clinical success From drug discovery a successful drug (Phase I to approval) to approval Schematic ex
Slide 11: Helping researchers in the labs to accelerate drug discovery
Helping researchers in the labs to accelerate drug discovery Our ambition Our solutions Reduce costly trial & error Powerful bioanalytical tools, cell models and lab essentials Understand diseases Conduct experiments Live cell analysis Cell characterization Protein analysis Cell selection Make bette
Slide 12: Once discovered also the manufacture of biologics remains complex
Once discovered also the manufacture of biologics remains complex 12
Slide 13: Providing technologies to increase productivity in bioprocessing
Providing technologies to increase productivity in bioprocessing Our ambition Our solutions More efficient bioprocessing Technologies for all phases of drug manufacturing Set up safe and flexible processes Increase resource and material efficiency Media & reagents Bioreactors & fermenters Reduce inv
Slide 14: Offering integrated end-to-end manufacturing solutions
Offering integrated end-to-end manufacturing solutions Upstream Production of the desired drug Cell culture media & Seed Scale-up Production preparation cultivation Downstream Isolation and filling of the desired drug Final Cryo- Sterile Concen- Virus clearance Chroma- Clarification & filling preser
Slide 15: Pioneering the industry: New platform supports transition from batch to continuous bioprocesses
Pioneering the industry: New platform supports transition from batch to continuous bioprocesses Today Future Pionic® Cooperation with Batch- Continuous Production Production Lower production costs Higher productivity Shorter time-to-market Spin Dual Fewer CO2-emissions 2025 2026 15
Slide 16: Cell and gene therapies: New modalities, new challenges
Cell and gene therapies: New modalities, new challenges Next generation biopharmaceuticals Enabling CGT: High need for innovation Viral Vectors mRNA Stem Cells Exosomes DNA New Vaccines Robustness of production process Yields, productivity, cost-per-dose Innovative treatments for patients Time-to-ma
Slide 17: Extensive technology platform for cell and gene therapy applications
Extensive technology platform for cell and gene therapy applications Up & downstream solutions Biological Albumedix Polyplus CellGenix Xell Industries Cell line development, Cell culture Growth factors Media and Recombinant Transfection plasmid design & media and cytokines supplements Albumin reagen
Slide 18: How we innovate
How we innovate Own Product Development Acquisitions Cooperations in areas of core competencies of complementary technologies with partners leading in their fields Process Separation Cell cultivation Media & reagents Chromatography Bioprinting intensification technologies Bioanalytical Lab analysis
Slide 19: Ongoing investment in innovation, growth and resilience
Ongoing investment in innovation, growth and resilience Songdo, South Korea Sterile consumables, labs Göttingen, Germany Nottingham, UK Filter Cell culture components Freiburg, Germany Bielefeld, Germany Cell culture components Media 2025 €442mn 12.5 % Investment Investment ratio 19
Slide 20: Strong financial track record; sustainable, profitable growth
Strong financial track record; sustainable, profitable growth High volatility during and post pandemic Ø Annual growth 4100 ~12% 2015-2025 59.5 ~€3.5bn 3900 57.5 55.5 3700 53.5 3500 51.5 3300 49.5 3100 47.5 2900 45.5 2700 43.5 2500 41.5 2300 39.5 34.1 2100 1900 33.8 37.5 35.5 29.7 1700 29.6 33.5 150
Slide 21: Ambitious mid-term climate agenda in line with Paris Climate Agreement
Ambitious mid-term climate agenda in line with Paris Climate Agreement 2030 mid-term ambitions 2045 long-term ambition Net-zero Scope 1 & 2 Scope 3 emissions 42% 51.6% Reduction of GHG emissions Reduction of GHG emissions relative compared to 2022 to value added1 compared to 2022 Use of renewable en
Slide 22: Simplifying Progress
Simplifying Progress Sartorius AG Corporate Communications & IR Otto-Brenner-Straße 20 37079 Göttingen Germany